By a News Reporter-Staff News Editor at Journal of Technology -- Investigators publish new report on Immunology. According to news reporting out of South San Francisco, California, by VerticalNews editors, research stated, "Antibody-drug conjugates (ADCs) are monoclonal antibodies with covalently bound cytotoxic drugs. They are designed to target tumor antigens selectively and offer the hope of cancer treatment without the debilitating side-effects of conventional therapies."
Our news journalists obtained a quote from the research from Genentech, "The concept of ADCs is not new; however, development of these therapeutics is challenging and only recently are promising clinical data emerging. These challenges include ADC bioanalysis, such as quantifying in serum/plasma for PK studies and strategies for assessing immunogenicity. ADCs have complex molecular structures incorporating large-and small-molecule characteristics and require diverse analytical methods, including ligand-binding assays and MS-based methods. ADCs are typically mixtures with a range of drug-to-antibody ratios. Biotransformations in vivo can lead to additional changes in drug-to-antibody ratios resulting in dynamically changing mixtures. Thus, a standard calibration curve consisting of the reference standard may not be appropriate for quantification of analytes in vivo and represents a unique challenge. This paper will share our perspective on why ADC bioanalysis is so complex and describe the strategies and rationale that we have used for ADCs, with highlights of original data from a variety of nonclinical and clinical case studies."
According to the news editors, the research concluded: "Our strategy has involved novel protein structural characterization tools to help understand ADC biotransformations in vivo and use of the analyte knowledge gained to guide the development of quantitative bioanalytical assays."
For more information on this research see: Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis, 2013;5(2):201-26.
Our news journalists report that additional information may be obtained by contacting S. Kaur, Genentech, 1 DNA Way, South San Francisco, CA 94080-4990, United States. Additional authors for this research include K. Xu, O.M. Saad, R.C. Dere and M. Carrasco-Triguero.
Keywords for this news article include: Antibodies, California, Immunology, United States, Blood Proteins, Immunoglobulins, South San Francisco, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC